The Toronto Upper Gastrointestinal Cleaning Score: a prospective validation study.
Journal
Endoscopy
ISSN: 1438-8812
Titre abrégé: Endoscopy
Pays: Germany
ID NLM: 0215166
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
pubmed:
2
6
2022
medline:
31
1
2023
entrez:
1
6
2022
Statut:
ppublish
Résumé
BACKGROUND : Assessment of mucosal visualization during esophagogastroduodenoscopy (EGD) can be improved with a standardized scoring system. To address this need, we created the Toronto Upper Gastrointestinal Cleaning Score (TUGCS). METHODS : We developed the TUGCS using Delphi methodology, whereby an international group of endoscopy experts iteratively rated their agreement with proposed TUGCS items and anchors on a 5-point Likert scale. After each Delphi round, we analyzed responses and refined the TUGCS using an 80 % agreement threshold for consensus. We used the intraclass correlation coefficient (ICC) to assess inter-rater and test-retest reliability. We assessed internal consistency with Cronbach's alpha and item-total and inter-item correlations with Pearson's correlation coefficient. We compared TUGCS ratings with an independent endoscopist's global rating of mucosal visualization using Spearman's ρ. RESULTS : We achieved consensus with 14 invited participants after three Delphi rounds. Inter-rater reliability was high at 0.79 (95 %CI 0.64-0.88). Test-retest reliability was excellent at 0.83 (95 %CI 0.77-0.87). Cronbach's α was 0.81, item-total correlation range was 0.52-0.70, and inter-item correlation range was 0.38-0.74. There was a positive correlation between TUGCS ratings and a global rating of visualization (r = 0.41,
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121-128Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
R. Khan has received research grants from AbbVie (2018) and Ferring Pharmaceuticals (2019), and research funding from Pendopharm (2019). S.C. Grover has received research grants and personal fees from AbbVie and Ferring Pharmaceuticals, personal fees from Takeda, education grants from Janssen, and has equity in Volo Healthcare. N. Gimpaya, J.I. Vargas, A. Ramkissoon, S. Seleq, R. Gholami, H.J. Akhtar, R. Bansal, M.A. Scaffidi, S. Amin, S. Bollipo, J. Kral, R. Lui, K.M. Pawlak, D. Sandhu, M. Bilal, E. de-Madaria, K. Siau, A. Charabaty, A. Hashim, S.A. Sánchez-Luna, C.W. Teshima, G.R. May, J.D. Mosko, and C.M. Walsh declare that they have no conflict of interest.